UBS Asset Management Americas Inc. increased its position in shares of Zoetis Inc (NYSE:ZTS) by 1.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,849,269 shares of the company’s stock after acquiring an additional 25,943 shares during the quarter. UBS Asset Management Americas Inc. owned about 0.38% of Zoetis worth $133,221,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Zoetis during the 4th quarter worth approximately $108,000. Steward Partners Investment Advisory LLC bought a new position in shares of Zoetis during the 3rd quarter worth approximately $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in shares of Zoetis by 251.9% during the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after acquiring an additional 1,360 shares in the last quarter. Shine Investment Advisory Services Inc. raised its stake in shares of Zoetis by 86.5% during the 3rd quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock worth $143,000 after acquiring an additional 1,040 shares in the last quarter. Finally, Advisory Services Network LLC grew its position in Zoetis by 42.4% during the 4th quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock worth $175,000 after purchasing an additional 721 shares during the last quarter. Hedge funds and other institutional investors own 94.18% of the company’s stock.
Zoetis Inc (NYSE:ZTS) opened at $79.73 on Tuesday. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77. Zoetis Inc has a 12 month low of $52.25 and a 12 month high of $81.40. The stock has a market cap of $38,689.28, a price-to-earnings ratio of 45.56, a P/E/G ratio of 1.80 and a beta of 1.06.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the previous year, the business posted $0.47 EPS. The business’s revenue was up 14.3% compared to the same quarter last year. research analysts anticipate that Zoetis Inc will post 3.02 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be paid a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.63%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio is currently 28.57%.
Several analysts have weighed in on ZTS shares. Zacks Investment Research downgraded shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price on the stock. in a research report on Saturday, January 13th. Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price objective on the stock in a report on Wednesday, November 29th. Jefferies Group reaffirmed a “buy” rating on shares of Zoetis in a report on Friday, November 10th. Craig Hallum reaffirmed a “buy” rating and issued a $85.00 price objective (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, BidaskClub raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $79.83.
TRADEMARK VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://ledgergazette.com/2018/02/20/zoetis-inc-zts-position-lifted-by-ubs-asset-management-americas-inc.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.